NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Clean Science and Technology reported a 12.2% YoY growth in consolidated revenue from operations, reaching ₹2,185.5 million for Q3 FY26. However, consolidated net profit saw a decline of approximately 11% YoY, coming in at ₹459.3 million compared to ₹516.1 million in the same quarter last year. The Board has declared an interim dividend of ₹2 per share (200% of face value) with a record date of February 6, 2026. The decline in profit despite revenue growth suggests pressure on margins or increased operational costs during the period.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations grew 12.2% YoY to ₹2,185.5 million in Q3 FY26.Consolidated Net Profit decreased by 11% YoY to ₹459.3 million from ₹516.1 million.Declared an interim dividend of ₹2 per equity share (200% on face value of ₹1).Record date for dividend eligibility is February 6, 2026, with payment by February 23, 2026.Consolidated EPS for the quarter declined to ₹4.32 from ₹4.86 in the year-ago period.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin compression as net profit fell despite double-digit revenue growth. While the dividend provides a yield, the bottom-line performance suggests rising input or operational costs that need further investigation.
Clean Science Declares ₹2 Interim Dividend; Q3 PAT Declines to ₹45.8 Crore
Clean Science and Technology has announced an interim dividend of ₹2 per share (200% of face value) for FY 2025-26, with the record date set for February 6, 2026. The company's consolidated revenue for Q3 FY26 stood at ₹249.6 crore, showing growth over the ₹194.7 crore reported in the same quarter last year. However, net profit saw a decline to ₹45.8 crore from ₹56.7 crore YoY and ₹65.7 crore sequentially. The dividend payment is scheduled to be completed by February 23, 2026.
முக்கிய அம்சங்கள்
Interim dividend of ₹2 per equity share of face value ₹1 eachConsolidated Revenue from operations at ₹2,496.4 million for Q3 FY26Consolidated Net Profit (PAT) fell to ₹458.3 million vs ₹567.5 million YoYBasic EPS for the quarter decreased to ₹4.32 from ₹5.35 YoYRecord date for dividend eligibility is February 6, 2026
👀 கவனிக்க வேண்டியவை
Investors seeking the dividend must hold shares before the February 6 record date. While the dividend is a positive payout, the sequential and year-on-year decline in profitability suggests monitoring margin pressures in the specialty chemicals segment.
Clean Science and Technology reported a 28% year-on-year growth in consolidated revenue from operations, reaching ₹2,496.44 million for Q3 FY26. However, consolidated net profit declined significantly to ₹458.41 million from ₹633.29 million in the previous year's corresponding quarter, indicating margin pressure. On a standalone basis, the company maintained stability with a net profit of ₹651.25 million. To reward shareholders, the board declared an interim dividend of ₹2 per share (200% of face value) with a record date of February 6, 2026.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations rose 28% YoY to ₹2,496.44 million in Q3 FY26.Consolidated Net Profit fell to ₹458.41 million compared to ₹633.29 million in Q3 FY25.Declared an interim dividend of ₹2 per equity share (200%) for the financial year 2025-26.Standalone Net Profit remained steady at ₹651.25 million versus ₹630.48 million YoY.The record date for dividend eligibility is February 6, 2026, with payment scheduled by February 23, 2026.
👀 கவனிக்க வேண்டியவை
Investors should investigate the cause of the sharp decline in consolidated profit despite strong revenue growth, focusing on subsidiary performance and raw material costs. While the dividend is positive, the margin compression warrants a cautious approach until cost-efficiency improves.
Clean Science Invests ₹50 Crore in Subsidiary Clean Fino-Chem for Project Funding
Clean Science and Technology Limited (CSTL) has invested ₹50 crore in its wholly-owned subsidiary, Clean Fino-Chem Limited (CFCL), via a rights issue. The investment involved subscribing to 8,36,121 equity shares at a price of ₹598 per share (including a ₹588 premium). CFCL is a specialty chemicals manufacturer that has shown rapid growth, with turnover increasing from ₹1.92 crore in FY24 to ₹46.77 crore in FY25. This capital infusion is specifically earmarked to fund ongoing projects, indicating a focus on capacity expansion.
முக்கிய அம்சங்கள்
Investment of ₹50.00 crore in wholly-owned subsidiary Clean Fino-Chem Limited.Acquisition of 8,36,121 equity shares at ₹598 per share (₹10 face value + ₹588 premium).CFCL turnover grew significantly from ₹1.92 crore in FY24 to ₹46.77 crore in FY25.Capital will be utilized primarily for funding specialty chemical projects within the subsidiary.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of CFCL's projects as the subsidiary is scaling rapidly and becoming a meaningful contributor to consolidated revenue. The continued investment signals management's confidence in the specialty chemicals growth pipeline.
Clean Science Subsidiary Commences Commercial Production of Hydroquinone and Catechol
Clean Science and Technology's wholly-owned subsidiary, Clean Fino-Chem Limited, has officially started commercial production of Hydroquinone (HQ) and Catechol as of December 18, 2025. This expansion positions the company as a significant domestic manufacturer, aiming to capture market share through import substitution. The production of HQ is strategically designed to create cross-selling opportunities with existing MEHQ customers and enhance the company's TBHQ market presence. Furthermore, Catechol will be used for captive consumption in the manufacturing of Guaiacol and Veratrole, improving vertical integration.
முக்கிய அம்சங்கள்
Commenced commercial production of Hydroquinone and Catechol on December 18, 2025Aims to become a key domestic manufacturer to drive import substitution in specialty chemicalsHQ production creates cross-selling opportunities with MEHQ customers and strengthens TBHQ market shareCatechol will be captively consumed for the production of Guaiacol and VeratroleProject highlights robust in-house R&D and synergistic project engineering capabilities
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant growth milestone that enhances vertical integration and market reach. Monitor the revenue contribution from these new lines in the upcoming quarterly results to assess the speed of market penetration.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Clean Science Appoints Siddhartha Sikchi as MD; Ashok Boob as Vice Chairman Effective April 2026
Clean Science and Technology Limited has received shareholder approval for a significant leadership transition effective April 1, 2026. Mr. Siddhartha Ashok Sikchi will take over as Managing Director for a five-year term, while the current MD, Mr. Ashok Ramnarayan Boob, will transition to the role of Executive Vice Chairman. Additionally, the company secured approval for the appointment and re-appointment of four Independent Directors, ensuring board stability. These resolutions were passed via postal ballot with over 99% of votes in favor for most items, indicating strong shareholder support for the succession plan.
முக்கிய அம்சங்கள்
Mr. Siddhartha Ashok Sikchi appointed as Managing Director for a 5-year term starting April 1, 2026.Current MD Mr. Ashok Ramnarayan Boob to transition to Executive Vice Chairman role from April 2026 to July 2027.Four Independent Directors (Madhu Dubhashi, Keval Doshi, Raj Kamal, Pallavi Gokhale) appointed or re-appointed to the board.Resolutions passed with high majority; for instance, the MD appointment received over 99.9% approval from voting members.
👀 கவனிக்க வேண்டியவை
This is a planned leadership transition within the promoter group, suggesting continuity in corporate strategy and operational philosophy. Investors should monitor the transition in 2026, but the move is currently viewed as a routine and stable succession process.
Clean Science Shareholders Approve Leadership Transition; Siddhartha Sikchi to be MD from April 2026
Clean Science and Technology Limited has received shareholder approval for a significant leadership transition effective April 1, 2026. Mr. Siddhartha Ashok Sikchi will take over as Managing Director for a five-year term, while the current MD, Mr. Ashok Ramnarayan Boob, will transition to the role of Executive Vice Chairman. Additionally, the company secured approvals for the appointment and re-appointment of four Independent Directors, ensuring board stability and regulatory compliance through 2030-2031.
முக்கிய அம்சங்கள்
Mr. Siddhartha Ashok Sikchi appointed as Managing Director for a 5-year term starting April 1, 2026.Current MD Mr. Ashok Ramnarayan Boob to transition to Executive Vice Chairman from April 2026 to July 2027.Re-appointment of Mr. Keval Navinchandra Doshi as Independent Director for 5 years approved with 99.46% votes.New Independent Directors Mr. Raj Kamal and Ms. Pallavi Gokhale appointed for 5-year terms starting November 2025.Resolution to continue Ms. Madhu Dubhashi's directorship past age 75 passed with 99.92% majority.
👀 கவனிக்க வேண்டியவை
The planned leadership transition indicates strong succession planning and reduces management uncertainty. Investors should maintain their positions as the core leadership remains involved in the company's strategic direction.
Clean Science Shareholders Approve New MD and Board Appointments for 5-Year Terms
Clean Science and Technology Limited has received shareholder approval via postal ballot for several key leadership transitions. Mr. Siddhartha Ashok Sikchi will take over as Managing Director for a five-year term starting April 1, 2026, while Mr. Ashok Ramnarayan Boob moves to the role of Executive Vice Chairman. The board also adds Mr. Raj Kamal and Ms. Pallavi Gokhale as Independent Directors for five-year tenures. These appointments, along with the re-appointment of Mr. Keval Doshi, reflect a structured approach to governance and succession planning.
முக்கிய அம்சங்கள்
Mr. Siddhartha Ashok Sikchi appointed as Managing Director for a 5-year term effective April 1, 2026.Mr. Raj Kamal and Ms. Pallavi Gokhale join as Independent Directors for 5-year terms starting Nov 6, 2025.Mr. Ashok Ramnarayan Boob to serve as Executive Vice Chairman from April 2026 to July 2027.Resolution for Mr. Raj Kamal's appointment passed with significant majority through postal ballot e-voting.Mr. Keval Navinchandra Doshi re-appointed as Independent Director for a second 5-year term until 2031.
👀 கவனிக்க வேண்டியவை
Investors should note the planned leadership transition in 2026 as a sign of stable succession planning. No immediate action is required as the changes maintain governance continuity.
Clean Science Approves MD Succession and Re-appointment of Independent Directors
Clean Science and Technology Limited has announced the approval of several key leadership transitions via postal ballot. Mr. Siddhartha Ashok Sikchi will take over as Managing Director for a 5-year term starting April 1, 2026, while current MD Mr. Ashok Ramnarayan Boob will transition to Executive Vice Chairman. Shareholders also approved the re-appointment of Mr. Keval Navinchandra Doshi as an Independent Director for another 5-year term starting February 2026. These resolutions were passed with high majorities, with the re-appointment of Mr. Doshi receiving 99.46% favorable votes.
முக்கிய அம்சங்கள்
Mr. Siddhartha Ashok Sikchi appointed as Managing Director for a 5-year term effective April 1, 2026.Mr. Ashok Ramnarayan Boob to transition to Whole Time Director - Executive Vice Chairman from April 1, 2026.Mr. Keval Navinchandra Doshi re-appointed as Independent Director for 5 years (2026-2031) with 99.46% approval.New Independent Directors Mr. Raj Kamal and Ms. Pallavi Gokhale appointed for 5-year terms starting November 2025.Total of 84.38 million votes polled across resolutions, reflecting strong shareholder participation.
👀 கவனிக்க வேண்டியவை
Investors should view the clear succession planning and the retention of founding members in strategic roles as a sign of long-term stability. No immediate action is required as the primary leadership transition is scheduled for 2026.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
